Vertical Longevity Pharma
@velopharma.bsky.social
We develop immunotherapies against the hallmarks of aging. By addressing a root driver of aging, we can intervene in numerous age-related diseases simultaneously. First in our crosshairs? Reversing atherosclerosis, the leading cause of global death.
Let’s do this together. Let’s put longevity in the hands of everyone.
🔗 netcapital.com/companies/ve...
#Longevity #Biotech #AgingScience #Healthspan #Senolytics #Immunotherapy #CardiovascularHealth #StartupFunding #InvestInScience #VeteranFounded #WomenLed
🔗 netcapital.com/companies/ve...
#Longevity #Biotech #AgingScience #Healthspan #Senolytics #Immunotherapy #CardiovascularHealth #StartupFunding #InvestInScience #VeteranFounded #WomenLed
Learn about Vertical Longevity Pharma - Netcapital
We’re developing a senolytic approach to reverse atherosclerosis – the leading cause of death – and extend healthy lifespan. Our platform targets aging at its root, with potential to treat multiple ag...
netcapital.com
December 11, 2025 at 9:49 PM
Let’s do this together. Let’s put longevity in the hands of everyone.
🔗 netcapital.com/companies/ve...
#Longevity #Biotech #AgingScience #Healthspan #Senolytics #Immunotherapy #CardiovascularHealth #StartupFunding #InvestInScience #VeteranFounded #WomenLed
🔗 netcapital.com/companies/ve...
#Longevity #Biotech #AgingScience #Healthspan #Senolytics #Immunotherapy #CardiovascularHealth #StartupFunding #InvestInScience #VeteranFounded #WomenLed
It’s for this very reason that our community investment round will remain open until January 16th. Anyone can participate, no investor accreditation required, with a $100 minimum investment to minimize barriers to entry.
December 11, 2025 at 9:49 PM
It’s for this very reason that our community investment round will remain open until January 16th. Anyone can participate, no investor accreditation required, with a $100 minimum investment to minimize barriers to entry.
With the funds already secured, we’re now prepared to initiate a primate study, which is a milestone that fewer than 1% of biotech companies ever reach.
As a human-first organization, part of our mission is to provide equitable access to our therapeutics and any upside that may follow.
As a human-first organization, part of our mission is to provide equitable access to our therapeutics and any upside that may follow.
December 11, 2025 at 9:49 PM
With the funds already secured, we’re now prepared to initiate a primate study, which is a milestone that fewer than 1% of biotech companies ever reach.
As a human-first organization, part of our mission is to provide equitable access to our therapeutics and any upside that may follow.
As a human-first organization, part of our mission is to provide equitable access to our therapeutics and any upside that may follow.
For those that missed it, Vertical Longevity is working to democratize access to advanced longevity therapeutics with a first-in-class senolytic immunotherapy. Our first-launch focus is the unclogging of arteries, directly addressing strokes, heart attacks, and the leading cause of global death.
December 11, 2025 at 9:49 PM
For those that missed it, Vertical Longevity is working to democratize access to advanced longevity therapeutics with a first-in-class senolytic immunotherapy. Our first-launch focus is the unclogging of arteries, directly addressing strokes, heart attacks, and the leading cause of global death.
Notable highlights included Chris Patil's (BioAge Labs) exceptional panel moderation skills, Gary J. Alan’s (ALSAE) eloquent explanation of longevity story arcs, and Matt Campen delivering a masterclass talk on microplastics.
December 11, 2025 at 9:49 PM
Notable highlights included Chris Patil's (BioAge Labs) exceptional panel moderation skills, Gary J. Alan’s (ALSAE) eloquent explanation of longevity story arcs, and Matt Campen delivering a masterclass talk on microplastics.
And now, you can own a piece of that mission, no investor accreditation required.
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
#Biotech #Longevity #HealthTech #LifeSciences #VentureCapital #Startup #Crowdfunding #LongBio #HeartDisease #Atherosclerosis #Senolytics
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
#Biotech #Longevity #HealthTech #LifeSciences #VentureCapital #Startup #Crowdfunding #LongBio #HeartDisease #Atherosclerosis #Senolytics
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
November 4, 2025 at 8:39 PM
And now, you can own a piece of that mission, no investor accreditation required.
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
#Biotech #Longevity #HealthTech #LifeSciences #VentureCapital #Startup #Crowdfunding #LongBio #HeartDisease #Atherosclerosis #Senolytics
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
#Biotech #Longevity #HealthTech #LifeSciences #VentureCapital #Startup #Crowdfunding #LongBio #HeartDisease #Atherosclerosis #Senolytics
At Vertical Longevity Pharma, we’re developing a first-in-class senolytic immunotherapy to target the drivers of aging and heart disease, with the broader vision of extending human healthspan across multiple age-related conditions.
November 4, 2025 at 8:39 PM
At Vertical Longevity Pharma, we’re developing a first-in-class senolytic immunotherapy to target the drivers of aging and heart disease, with the broader vision of extending human healthspan across multiple age-related conditions.
And now, you can own a piece of that mission, no investor accreditation required.
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
🎙️ Check out the podcast:
🔗 www.bioinformaticscro.com/podcast/davi...
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
🎙️ Check out the podcast:
🔗 www.bioinformaticscro.com/podcast/davi...
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
October 23, 2025 at 6:27 PM
And now, you can own a piece of that mission, no investor accreditation required.
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
🎙️ Check out the podcast:
🔗 www.bioinformaticscro.com/podcast/davi...
👉 Our community round is officially live:
🔗 netcapital.com/companies/ve...
🎙️ Check out the podcast:
🔗 www.bioinformaticscro.com/podcast/davi...
At Vertical Longevity Pharma, we’re developing a first-in-class senolytic immunotherapy to target the drivers of aging and heart disease, with the broader vision of extending human healthspan across multiple age-related conditions.
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
October 23, 2025 at 6:27 PM
At Vertical Longevity Pharma, we’re developing a first-in-class senolytic immunotherapy to target the drivers of aging and heart disease, with the broader vision of extending human healthspan across multiple age-related conditions.
We are building therapies that strike the balance: measurable in the clinic and meaningful in life. If you have an interest in human longevity, follow along. We are just getting started.
October 6, 2025 at 9:20 PM
We are building therapies that strike the balance: measurable in the clinic and meaningful in life. If you have an interest in human longevity, follow along. We are just getting started.
Vertical Longevity Pharma focuses on a replaceable cell subset, where senescent clearance restores function and safety margins are high.
October 6, 2025 at 9:20 PM
Vertical Longevity Pharma focuses on a replaceable cell subset, where senescent clearance restores function and safety margins are high.
Target too many senescent cell types and you risk injury, especially when environmental insults like wildfire smoke can push sensitive cells toward senescence. Target too few and benefit is negligible.
October 6, 2025 at 9:20 PM
Target too many senescent cell types and you risk injury, especially when environmental insults like wildfire smoke can push sensitive cells toward senescence. Target too few and benefit is negligible.
A practical route is selective removal of senescent cells that are replaceable by stem cells. Not all tissues qualify. In the heart, many cardiomyocytes are irreplaceable, so indiscriminate killing would do harm.
October 6, 2025 at 9:20 PM
A practical route is selective removal of senescent cells that are replaceable by stem cells. Not all tissues qualify. In the heart, many cardiomyocytes are irreplaceable, so indiscriminate killing would do harm.
Clinically, patching every leaking lysosome sounds elegant, but biology is not a single screw to tighten. The pathways are complex and intertwined, and broad repair is not ready for safe human use.
October 6, 2025 at 9:20 PM
Clinically, patching every leaking lysosome sounds elegant, but biology is not a single screw to tighten. The pathways are complex and intertwined, and broad repair is not ready for safe human use.
This damage aligns with other hallmarks of aging, like genomic instability, epigenetic drift, mitochondrial dysfunction, loss of proteostasis, dysregulated nutrient sensing, oxidative stress, and impaired autophagy. Importantly, senescent cells have measurable markers, including acidity.
October 6, 2025 at 9:20 PM
This damage aligns with other hallmarks of aging, like genomic instability, epigenetic drift, mitochondrial dysfunction, loss of proteostasis, dysregulated nutrient sensing, oxidative stress, and impaired autophagy. Importantly, senescent cells have measurable markers, including acidity.
Inside every cell are acid-filled recyclers called lysosomes. They dissolve worn-out parts into building blocks the cell can reuse. With age, lysosomes can leak, and escaped acid injures mitochondria, DNA, and the protein factories, tipping cells toward senescence.
October 6, 2025 at 9:20 PM
Inside every cell are acid-filled recyclers called lysosomes. They dissolve worn-out parts into building blocks the cell can reuse. With age, lysosomes can leak, and escaped acid injures mitochondria, DNA, and the protein factories, tipping cells toward senescence.
Senescence often follows accumulated stresses, like DNA damage, chronic inflammation, and reductions in the protective end-caps on DNA (telomeres). The cell survives, but its behavior changes.
October 6, 2025 at 9:20 PM
Senescence often follows accumulated stresses, like DNA damage, chronic inflammation, and reductions in the protective end-caps on DNA (telomeres). The cell survives, but its behavior changes.
We longevity biotechnologists fight aging not because it is easy, but because it is necessary. We audaciously seek to restore the metropolis of life, fighting decay and boldly disregarding those telling us that potholes in roads are a natural part of life. Join us, and join the fight against aging.
August 27, 2025 at 3:40 PM
We longevity biotechnologists fight aging not because it is easy, but because it is necessary. We audaciously seek to restore the metropolis of life, fighting decay and boldly disregarding those telling us that potholes in roads are a natural part of life. Join us, and join the fight against aging.
We’ve taken a hard look at the science, and we view senescence as a driver of many other civic breakdowns. Crucially, these cells can be cleared, and their removal allows districts to repopulate with young, fit workers eager to build, repair, and protect.
August 27, 2025 at 3:40 PM
We’ve taken a hard look at the science, and we view senescence as a driver of many other civic breakdowns. Crucially, these cells can be cleared, and their removal allows districts to repopulate with young, fit workers eager to build, repair, and protect.
• Altered intercellular communication: phone and internet lines fail.
Over time, these failures compound. Infrastructure cracks, districts weaken, and citizens lose capacity. But decline is not destiny.
Over time, these failures compound. Infrastructure cracks, districts weaken, and citizens lose capacity. But decline is not destiny.
August 27, 2025 at 3:40 PM
• Altered intercellular communication: phone and internet lines fail.
Over time, these failures compound. Infrastructure cracks, districts weaken, and citizens lose capacity. But decline is not destiny.
Over time, these failures compound. Infrastructure cracks, districts weaken, and citizens lose capacity. But decline is not destiny.